Stock listing
NASDAQ:VANI Vivani Medical, Inc. Stock
Home listing (NASDAQ) of Vivani Medical, Inc.
Follow Vivani Medical, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:VANI
$1.14 USD +0.09 (+8.6%)
Close on Nov 20, 2026
- Day range
- $1.10 – $1.16 USDNov 20, 2026
- Volume
- 448,602 sharesNov 20, 2026
- Market cap
- $102.8M USDAt the close on Nov 20, 2026 · price × 90.20M shares outstanding
- 52-week range
- $0.80 – $1.66 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $266,975 USDMedian day 177,180 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VANI · Home | $1.14 USD | +0.09 (+8.6%) | 448,602 | $1.14 | $1.155 | $1.10 | $1.05 | Close on Nov 20, 2026 |
| Frankfurt:U5P | €0.97 EUR | +0.045 (+4.9%) | — | €0.90 | €0.97 | €0.90 | €0.925 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VANI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.14 | +0.09 | +8.6% | $1.14 | $1.155 | $1.10 | 448,602 | |
| $1.05 | 0.00 | 0.0% | $1.02 | $1.08 | $1.02 | 177,180 | |
| $1.05 | +0.03 | +2.9% | $1.02 | $1.089 | $0.992 | 260,144 | |
| $1.02 | +0.01 | +1.0% | $1.05 | $1.11 | $1.01 | 459,680 | |
| $1.01 | +0.027 | +2.7% | $0.97 | $1.03 | $0.888 | 367,707 | |
| $0.983 | -0.147 | -13.0% | $1.12 | $1.12 | $0.80 | 1,391,414 | |
| $1.13 | -0.02 | -1.7% | $1.15 | $1.16 | $1.115 | 135,209 | |
| $1.15 | +0.025 | +2.2% | $1.15 | $1.16 | $1.09 | 170,230 | |
| $1.125 | +0.055 | +5.1% | $1.09 | $1.14 | $1.08 | 108,163 | |
| $1.07 | +0.03 | +2.9% | $1.04 | $1.098 | $1.04 | 262,143 | |
| $1.04 | -0.03 | -2.8% | $1.07 | $1.10 | $1.01 | 401,190 | |
| $1.07 | +0.02 | +1.9% | $1.08 | $1.085 | $1.04 | 180,969 | |
| $1.05 | -0.04 | -3.7% | $1.09 | $1.13 | $1.04 | 282,605 | |
| $1.09 | 0.00 | 0.0% | $1.13 | $1.16 | $1.084 | 185,517 | |
| $1.09 | -0.05 | -4.4% | $1.12 | $1.12 | $1.07 | 185,033 | |
| $1.14 | 0.00 | 0.0% | $1.13 | $1.195 | $1.125 | 190,037 | |
| $1.14 | 0.00 | 0.0% | $1.12 | $1.16 | $1.07 | 266,470 | |
| $1.14 | +0.01 | +0.9% | $1.12 | $1.175 | $1.12 | 197,521 | |
| $1.13 | +0.02 | +1.8% | $1.11 | $1.15 | $1.11 | 122,499 | |
| $1.11 | +0.02 | +1.8% | $1.08 | $1.11 | $1.075 | 85,800 | |
| $1.09 | -0.07 | -6.0% | $1.121 | $1.135 | $1.065 | 241,000 | |
| $1.16 | +0.04 | +3.6% | $1.13 | $1.17 | $1.12 | 161,200 | |
| $1.12 | 0.00 | 0.0% | $1.13 | $1.155 | $1.11 | 89,600 | |
| $1.12 | 0.00 | 0.0% | $1.12 | $1.14 | $1.10 | 80,400 | |
| $1.12 | -0.03 | -2.6% | $1.15 | $1.165 | $1.10 | 361,600 | |
| $1.15 | -0.01 | -0.9% | $1.15 | $1.17 | $1.15 | 108,400 | |
| $1.16 | -0.02 | -1.7% | $1.17 | $1.186 | $1.16 | 157,100 | |
| $1.18 | -0.01 | -0.8% | $1.19 | $1.19 | $1.16 | 269,100 | |
| $1.19 | -0.06 | -4.8% | $1.22 | $1.23 | $1.19 | 146,500 | |
| $1.25 | +0.02 | +1.6% | $1.22 | $1.25 | $1.21 | 101,900 | |
| $1.23 | -0.04 | -3.1% | $1.26 | $1.31 | $1.19 | 260,700 | |
| $1.27 | +0.03 | +2.4% | $1.25 | $1.335 | $1.242 | 272,400 | |
| $1.24 | +0.02 | +1.6% | $1.24 | $1.26 | $1.22 | 100,600 | |
| $1.22 | -0.01 | -0.8% | $1.22 | $1.25 | $1.22 | 95,200 | |
| $1.23 | +0.01 | +0.8% | $1.25 | $1.25 | $1.23 | 88,200 | |
| $1.22 | -0.02 | -1.6% | $1.23 | $1.26 | $1.22 | 63,800 | |
| $1.24 | +0.01 | +0.8% | $1.24 | $1.27 | $1.24 | 119,100 | |
| $1.23 | -0.02 | -1.6% | $1.25 | $1.25 | $1.22 | 82,900 | |
| $1.25 | +0.01 | +0.8% | $1.24 | $1.27 | $1.23 | 107,000 | |
| $1.24 | +0.01 | +0.8% | $1.25 | $1.26 | $1.23 | 128,200 | |
| $1.23 | 0.00 | 0.0% | $1.23 | $1.24 | $1.22 | 80,200 | |
| $1.23 | -0.04 | -3.1% | $1.26 | $1.27 | $1.21 | 149,100 | |
| $1.27 | +0.03 | +2.4% | $1.24 | $1.31 | $1.24 | 174,900 | |
| $1.24 | +0.05 | +4.2% | $1.20 | $1.27 | $1.20 | 131,800 | |
| $1.19 | -0.02 | -1.7% | $1.22 | $1.229 | $1.17 | 904,500 | |
| $1.21 | -0.01 | -0.8% | $1.22 | $1.24 | $1.205 | 219,800 | |
| $1.22 | -0.01 | -0.8% | $1.23 | $1.24 | $1.215 | 141,800 | |
| $1.23 | -0.03 | -2.4% | $1.26 | $1.275 | $1.21 | 208,600 | |
| $1.26 | -0.01 | -0.8% | $1.26 | $1.284 | $1.24 | 150,500 | |
| $1.27 | +0.02 | +1.6% | $1.25 | $1.29 | $1.24 | 249,300 | |
| $1.25 | -0.065 | -4.9% | $1.31 | $1.31 | $1.25 | 254,300 | |
| $1.315 | -0.04 | -3.0% | $1.36 | $1.36 | $1.315 | 282,500 | |
| $1.355 | -0.135 | -9.1% | $1.50 | $1.50 | $1.34 | 465,800 | |
| $1.49 | +0.10 | +7.2% | $1.40 | $1.515 | $1.38 | 475,100 | |
| $1.39 | -0.03 | -2.1% | $1.44 | $1.47 | $1.37 | 231,100 | |
| $1.42 | +0.06 | +4.4% | $1.37 | $1.45 | $1.37 | 140,400 | |
| $1.36 | -0.03 | -2.2% | $1.36 | $1.388 | $1.35 | 191,500 | |
| $1.39 | -0.03 | -2.1% | $1.44 | $1.48 | $1.37 | 208,200 | |
| $1.42 | +0.02 | +1.4% | $1.41 | $1.43 | $1.39 | 163,000 | |
| $1.40 | -0.015 | -1.1% | $1.42 | $1.42 | $1.395 | 86,700 | |
| $1.415 | -0.005 | -0.4% | $1.43 | $1.45 | $1.37 | 215,700 | |
| $1.42 | +0.04 | +2.9% | $1.38 | $1.42 | $1.34 | 200,718 | |
| $1.38 | 0.00 | 0.0% | $1.40 | $1.415 | $1.343 | 174,442 | |
| $1.38 | -0.03 | -2.1% | $1.44 | $1.44 | $1.365 | 104,700 | |
| $1.41 | +0.02 | +1.4% | $1.36 | $1.423 | $1.36 | 108,100 |
Splits
2 splits since 2020 · NASDAQ:VANI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-3 | Consolidation | |
| 1-for-8 | Consolidation |
- Ticker
- NASDAQ:VANI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Vivani Medical Announces Private Placement Equity Financing
Latest deck · Nov 16, 2026
Investor Presentation (November 2026)
Investor deck · 35 slides
Latest news
Vivani Medical Announces Private Placement Equity Financing
Nov 16, 2026
Closed $1.02 (+1.0%) on Nov 16, 2026
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
Nov 12, 2026
Closed $0.983 (-13.0%) on Nov 12, 2026
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 11, 2026
Closed $0.983 (-13.0%) on Nov 12, 2026
Vivani Medical Announces Participation in Upcoming Investor Conferences
Oct 12, 2026
Closed $1.19 (-4.8%) on Oct 12, 2026
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $1.40 (+4.5%) on Aug 14, 2026
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Aug 6, 2026
Closed $1.36 (-1.4%) on Aug 6, 2026
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Jul 14, 2026
Closed $1.41 (+0.7%) on Jul 15, 2026
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
Jul 2, 2026
Closed $1.26 (+2.4%) on Jul 2, 2026
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
Jun 26, 2026
Closed $1.20 (+5.3%) on Jun 26, 2026
Vivani Medical, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 101 in all · newest Nov 16, 2026 · oldest 2019
- Decks
- 44 decks · latest Nov 16, 2026
Where Vivani Medical, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VANI · Home listing · This page | NASDAQ | United States | USD |
| LS Exchange:A3DTRX | LS Exchange | Germany | EUR |
| gettex:U5P | gettex | Germany | EUR |
| Lang & Schwarz:A3DTRX | Lang & Schwarz | Germany | EUR |
| BOATS:VANI | BOATS | United States | USD |
| Dusseldorf:U5P | Dusseldorf | Germany | EUR |
| Frankfurt:U5P | Frankfurt | Germany | EUR |
| Munich:U5P | Munich | Germany | EUR |
| Stuttgart:U5P | Stuttgart | Germany | EUR |
| Tradegate:U5P | Tradegate | Germany | EUR |
Valuation
Price/book 7.8× against a median of 3.8×: 5th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $88.24M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 7.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.93
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Vivani Medical, Inc. · NASDAQ:VANI | US$102.8M | US$88.24M | n/a | n/a | n/a | 7.8× | n/a | 0.0× | 0.93 |
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Cardiol Therapeutics Inc. Class A · TSX:CRDL | US$103.4M | US$83.06M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.45 |
| Heidelberg Pharma AG · XETR:HPHA | US$103.2M | US$81.75M | n/a | 8.0× | n/a | n/a | −320.9% | n/a | n/a |
| Foghorn Therapeutics Inc. · NASDAQ:FHTX | US$103.1M | −US$9.22M | 10.9× | −0.1× | −2.5× | n/a | 8.4% | n/a | 1.57 |
| Paradigm Biopharmaceuticals Ltd. · ASX:PAR | US$101.6M | US$96.33M | n/a | 1,816× | n/a | 44.2× | n/a | 2.2× | n/a |
| Innate Pharma SA Class A · EURONEXT:IPH | US$101.5M | US$111.7M | n/a | 36.5× | n/a | n/a | n/a | n/a | n/a |
| BRIM Biotechnology, Inc. · TWSE:6885 | US$100.3M | US$70.71M | n/a | 220× | n/a | 2.1× | n/a | 0.0× | n/a |
| Minerva Neurosciences, Inc · NASDAQ:NERV | US$99.67M | US$22.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.68 |
| Median of the others | US$103.2M | US$82.41M | 10.9× | 36.5× | −2.5× | 3.8× | −195.8% | 0.0× | 1.55 |
Forecasts
2 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.83 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.32 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Adam Mendelsohn | Co-Founder & Chief Executive Officer |
| Anthony Baldor | Chief Financial Officer |
| Jami Taylor | Investor Relations |
| Don Dwyer | Chief Business Officer |
| Lisa Porter | Chief Medical Officer |
| Truc Le | Chief Operations Officer |
Board
| Director | Role |
|---|---|
| Gregg Williams | Director & Chairman of the Board |
| Aaron Mendelsohn | Member of the Board |
| Adam Mendelsohn | Co-Founder & Chief Executive Officer |
| Alexandra L. Popoff | Member of the Board |
| August J. Moretti | Member of the Board |
| Daniel Bradbury | Member of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 11, 2026 · After close | −13.0% |
| Q2 2026 | Aug 13, 2026 · After close | +4.5% |
| Q1 2026 | May 13, 2026 · After close | +3.5% |
| Q4 2025 | Mar 26, 2026 | −9.7% |
| Q3 2025 | Nov 13, 2025 · Before open | −11.4% |
| Q2 2025 | Aug 13, 2025 · After close | +0.8% |
| Q1 2025 | May 12, 2025 · Before open | −1.0% |
| Q4 2024 | Mar 31, 2025 · Before open | −5.4% |
| Q3 2024 | Nov 13, 2024 · Before open | +11.2% |
| Q2 2024 | Aug 13, 2024 · After close | +8.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · After close | −1.1% |
| Q4 2023 | Mar 26, 2024 · After close | −1.6% |
| Q3 2023 | Nov 13, 2023 · After close | −6.3% |
| Q2 2023 | Aug 14, 2023 · After close | −10.7% |
| Q1 2023 | May 15, 2023 · After close | −10.0% |
| Q4 2022 | Mar 31, 2023 · After close | −8.0% |
| Q3 2022 | Nov 14, 2022 · After close | −0.6% |
| Q2 2022 | Aug 10, 2022 | +3.6% |
| Q1 2022 | May 19, 2022 | +14.3% |
| Q4 2021 | Mar 10, 2022 | −3.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 35 slides | Nov 16, 2026 |
| Investor Presentation (November 2026) | Investor deck | 29 slides | November 2026 |
| Investor Presentation (October 2026) | Investor deck | 28 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 29 slides | Aug 17, 2026 |
| Investor Presentation (July 2026) | Investor deck | 18 slides | Jul 16, 2026 |
| Investor Presentation (June 2026) | Investor deck | 28 slides | Jun 4, 2026 |
| Corporate Update (November 2025) | Corporate update | 26 slides | Nov 13, 2025 |
| Investor Presentation (September 2025) | Investor deck | 26 slides | Sep 9, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 35 slides | Aug 13, 2025 |
| Investor Presentation (June 2025) | Investor deck | 39 slides | Jun 17, 2025 |
All 44 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$5.1M · US$1.01 a share Buyers: Gregg Williams; Aaron Mendelsohn Insiders: Purchased by Chairman Gregg Williams and director Aaron Mendelsohn Use of proceeds: Research and clinical development of NPM-139 semaglutide implant and other candidates, working capital and general corporate purposes | Nov 16, 2026 |
| Registered direct offering of shares of common stock Closed: US$1.48 a share · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes | Jan 27, 2026 |
| Private placement of shares of common stock Closed: US$1.48 a share Buyers: Gregg Williams (1,351,351 shares of common stock at $1.48 per share) Insiders: All shares purchased by Gregg Williams, Chairman of the board Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes | Jan 27, 2026 |
| Private placement of shares of common stock Announced: about US$10M · US$1.26 a share Buyers: entity beneficially owned by Gregg Williams Insiders: Two investors including an entity beneficially owned by Chairman Gregg Williams Use of proceeds: Secure financial position into second half of 2026 and accelerate development of NPM-139 into clinical-stage development | Aug 13, 2025 |
| Private placement of shares Update: about US$3M · US$1.03 a share | May 13, 2025 |
| Private placement of shares Announced: about US$8.25M · US$1.12 a share Buyers: Entity beneficially owned by Gregg Williams Insiders: The Company has entered into a securities purchase agreement with an entity beneficially owned by Gregg Williams, the Chairman of the board Use of proceeds: Extend cash runway into Q2 2026; accelerate development of NPM-139 semaglutide implant and continue development of NPM-115 | Mar 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as SECOND SIGHT MEDICAL PRODUCTS INC. Priced at US$9.00 a share on Nov 18, 2014.
- Price
- US$9.00 a share
- Shares offered
- 3,500,000 shares of common stock
- Offering size
- US$31.5 million
- Listing
- EYES on the Nasdaq Capital Market
- Underwriter
- MDB Capital Group, LLC
- Shares delivered
- On or about Nov 24, 2014
Steps
| Step | When |
|---|---|
| Filed publicly | Aug 12, 2014 |
| Amended 3 times | Newest Nov 14, 2014 |
| Shares registered with an exchange | Nov 14, 2014 |
| Declared effective by the SEC | Nov 18, 2014 |
| Final prospectus, with the price | Nov 20, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B3 · Prospectus | Nov 20, 2014 |
| EFFECT · Notice that a registration is effective | Nov 18, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Nov 17, 2014 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | Nov 17, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 14, 2014 |
| CORRESP · Letter to the SEC | Nov 14, 2014 |
| CORRESP · Letter to the SEC | Nov 14, 2014 |
| CORRESP · Letter to the SEC | Nov 14, 2014 |
| S-1/A · Registration statement, amended | Nov 14, 2014 |
| UPLOAD · Letter from the SEC | Nov 12, 2014 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 6, 2014 |
| S-1/A · Registration statement, amended | Nov 6, 2014 |
| UPLOAD · Letter from the SEC | Oct 23, 2014 |
| FWP · Free writing prospectus | Oct 6, 2014 |
| S-1/A · Registration statement, amended | Oct 2, 2014 |
| UPLOAD · Letter from the SEC | Sep 8, 2014 |
| S-1 · Registration statement | Aug 12, 2014 |
Open IPO · From the cover of the final prospectus (424B3) filed Nov 20, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 260 | 1.00K | 3.38M | 6.90M | 7.96M | 4.00M |
| Cost of revenue | 424.0K | 400.0K | 357.0K | 381.0K | 130.0K | 500.0K | 2.15M | 4.89M | 5.12M | 10.1M |
| Gross profit | -424.0K | -400.0K | -357.0K | -381.0K | 130.0K | 500.0K | 1.23M | 2.01M | 2.85M | -6.09M |
| Research and development | 18.1M | 15.7M | 17.0M | 14.2M | 11.0M | 4.84M | 13.1M | 10.0M | 7.89M | 5.35M |
| Selling, general and administrative | 9.43M | 8.93M | 10.00M | 5.37M | 2.32M | 2.38M | 9.23M | 10.7M | 10.9M | 10.1M |
| Operating income | -27.6M | -24.7M | -27.0M | -21.2M | -13.3M | -14.9M | -34.0M | -35.2M | -28.6M | -33.2M |
| Depreciation and amortization | 424.0K | 400.0K | 357.0K | 381.0K | 345.0K | 164.0K | 397.0K | 435.0K | 457.0K | 432.0K |
| EBITDA | -27.1M | -24.3M | -26.6M | -20.9M | -13.0M | -14.7M | -33.6M | -34.7M | -28.2M | -32.8M |
| Interest expense | 7.35M | 550.0K | 0 | 0 | 0 | |||||
| Income before tax | -26.6M | -23.5M | -25.7M | -13.9M | -12.8M | -9.28M | -33.6M | -35.1M | -28.5M | -33.2M |
| Income tax | 2.00K | -7.35M | -641.0K | 147.7K | 0 | 0 | 93.0K | 31.0K | ||
| Net income | -26.6M | -23.5M | -25.7M | -13.9M | -12.8M | -14.9M | -33.6M | -35.1M | -28.5M | -33.2M |
| Earnings per share, basic | -0.43 | -0.43 | -0.50 | -273.75 | -0.27 | -0.72 | -2.28 | -4.23 | -0.53 | -0.84 |
| Earnings per share, diluted | -0.43 | -0.43 | -0.50 | -0.27 | -0.72 | -2.28 | -4.23 | -0.53 | -0.84 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.2M | 18.4M | 20.7M | 45.1M | 2.18M | 2.08M | 11.3M | 4.47M | 7.84M | 10.9M |
| Short-term investments | 7.24M | 10.3M | ||||||||
| Receivables | 654.0K | 253.0K | 455.0K | 504.0K | 1.83M | 274.0K | ||||
| Inventory | 1.03M | 3.25M | 2.70M | 3.42M | ||||||
| Current assets | 17.9M | 20.4M | 23.1M | 47.5M | 2.47M | 4.27M | 13.1M | 9.62M | 13.2M | 15.3M |
| Property, plant and equipment | 2.88M | 1.69M | 1.73M | 1.18M | 1.17M | 174.0K | 1.12M | 1.02M | 1.30M | 1.49M |
| Total assets | 39.4M | 41.6M | 45.8M | 51.1M | 5.45M | 4.46M | 16.6M | 10.7M | 14.5M | 16.8M |
| Accounts payable | 1.03M | 817.0K | 542.0K | 1.18M | 281.0K | 486.0K | 1.09M | 1.30M | 752.0K | 1.16M |
| Current liabilities | 6.60M | 5.99M | 5.72M | 6.82M | 2.09M | 5.13M | 6.96M | 7.60M | 6.62M | 5.66M |
| Total debt | 18.9M | 19.3M | 20.7M | 955.0K | 1.81M | 2.47M | 2.60M | |||
| Total liabilities | 23.7M | 24.0M | 25.0M | 6.82M | 2.99M | 5.13M | 9.32M | 7.60M | 6.62M | 5.66M |
| Shareholders' equity | 15.7M | 17.6M | 20.8M | 44.3M | 2.46M | 1.95M | 7.28M | 3.08M | 7.88M | 11.1M |
| Shares outstanding | 76.4M | 59.2M | 51.0M | 50.7K | 36.8M | 23.2K | 15.6M | 9.54M | 57.6M | 42.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24.3M | -20.8M | -23.7M | -18.8M | -11.0M | -16.8M | -27.6M | -29.8M | -23.9M | -25.1M |
| Capital spending | -1.17M | -556.0K | -887.0K | -338.0K | -572.0K | -330.0K | -493.0K | -163.0K | -265.0K | -490.0K |
| Free cash flow | -25.5M | -21.3M | -24.6M | -19.1M | -11.5M | -17.2M | -28.1M | -30.0M | -24.2M | -25.6M |
| Cash from investing | -1.17M | -556.0K | -887.0K | -338.0K | -572.0K | 68.0K | -493.0K | -163.0K | -265.0K | -490.0K |
| Cash from financing | 23.3M | 19.1M | 133.0K | 63.4M | 11.6M | 8.60M | 35.0M | 26.6M | 21.2M | 20.5M |
| Share buybacks | -28.0K | -281.0K | ||||||||
| Change in cash | -2.12M | -2.30M | -24.4M | 44.3M | 97.0K | -8.15M | 6.86M | -3.37M | -3.04M | -5.08M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4/A · Change in ownership, amended | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2026 | Material contract | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 19, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Sep 25, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
| 8-K · Current report | Aug 17, 2026 | Current report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 16, 2026 | Current report | SEC |
| 8-K · Current report | Jul 7, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 30, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 19, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 27, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 27, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2025 | Current report | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2025 | Current report | SEC |
| 8-K · Current report | Jun 11, 2025 | Management or board change | SEC |
| 8-K · Current report | May 29, 2025 | Current report | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| DEFR14A | May 6, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Mar 27, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 26, 2025 | Current report | SEC |
| 8-K · Current report | Mar 13, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Oct 22, 2024 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Current report | SEC |
| 8-K · Current report | Sep 23, 2024 | Current report | SEC |
| 8-K · Current report | Sep 4, 2024 | Current report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 28, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 13, 2024 | Current report | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 2, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 2, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| UPLOAD · Letter from the SEC | Apr 29, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 22, 2024 | Material contract | SEC |
| S-3 · Registration statement | Apr 22, 2024 | Offer document | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 26, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Mar 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 5, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 5, 2024 | Offer document | SEC |
| 144 · Notice of proposed sale | Mar 5, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 28, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 27, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 24, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 11, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 18, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 28, 2023 | Material contract | SEC |
| 4 · Change in ownership | Aug 18, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 10, 2023 | Current report | SEC |
This page holds 200 of 847 filings. Open Filings
Cap table
Built by 6ix from Vivani Medical, Inc.’s releases · as of Nov 16, 2026
- Common shares
- 90,203,356
- Fully diluted
- 90,203,356
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 90,203,356 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 90,203,356 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William J. Link Other companies: RxSight, Inc. (Director · Since at least Jul 29, 2021); Tarsus Pharmaceuticals, Inc. (Director · Since at least Oct 15, 2020); LENSAR, Inc. (Director · Since at least Sep 17, 2020); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 5, 2022 · Past); Glaukos Corporation (Director · Jun 24, 2015 – Jun 3, 2021 · Past); Flexion Therapeutics Inc (Director · Sep 10, 2014 – Sep 10, 2014 · Past); Inogen, Inc (Director · Feb 12, 2014 – Feb 20, 2014 · Past); Edwards Lifesciences Corporation (Director · May 15, 2013 – May 8, 2020 · Past) | Director · Nov 18, 2014 – Jun 4, 2019 · Past |
| August Moretti Other companies: Cibus, Inc. (Director · Since at least Nov 18, 2024); 4D Molecular Therapeutics, Inc. (Chief Financial Officer · Dec 10, 2020 – May 15, 2023 · Past); Depomed Inc (Chief Financial Officer & SVP · Jan 3, 2012 – Mar 31, 2018 · Past); Alexza Pharmaceuticals Inc (Former SVP, CFO, GC & Sec · Mar 8, 2006 – Dec 31, 2011 · Past) | Member of the Board · Since at least Jun 24, 2026 |
| Brigid A. Makes Other companies: Elutia, Inc. (Board Member · Since at least May 29, 2025); Quantum-Si Incorporated (Director · Since at least May 19, 2025) | Chief Financial Officer · May 12, 2025 – May 12, 2025 · Past |
| William Patrick Ryan Other companies: Insulet Corporation (Chief Operating Officer · Jan 20, 2014 – May 5, 2015 · Past); Alphatec Holdings, Inc. (COO and President, Int'l. · Apr 25, 2011 – Aug 8, 2013 · Past) | Chief Operating Officer · Sep 1, 2018 – Feb 19, 2020 · Past |
| Aaron Mendelsohn | Member of the Board · Since at least Nov 18, 2014 |
| Adam Mendelsohn | Co-Founder & Chief Executive Officer · Since at least Oct 12, 2026 |
| Alexandra L. Popoff | Member of the Board · Since at least Jun 24, 2025 |
| Anne-Marie Juliette Ripley | VP of Regulatory Affairs · Nov 18, 2014 – Dec 4, 2015 · Past |
| Anthony Baldor | Chief Financial Officer · Since at least Jun 11, 2025 |
| Daniel Bradbury | Member of the Board · Since at least Nov 5, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Donald Dwyer | Chief Business Officer · Since at least Aug 30, 2022 |
| Gregg Williams | Director · Since at least May 18, 2022 |
| Gregoire Cosendai | VP Clinical Affairs · Nov 18, 2014 – Jan 4, 2018 · Past |
| Jami Taylor | Investor Relations · Since at least Jan 29, 2026 |
| John Anthony Moses | Commercial VP Americas · May 25, 2015 – Jan 21, 2016 · Past |
| Lisa Porter | Chief Medical Officer · Since at least Apr 16, 2025 |
| Matthew J Pfeffer | Director · Jun 1, 2018 – Jun 4, 2019 · Past |
| Stephen D Okland | Chief Commercial Officer · Mar 28, 2016 – Feb 19, 2019 · Past |
| Thomas B Miller | Chief Financial Officer · Jan 21, 2016 – Jan 19, 2018 · Past |
| Truc Le | Chief Operations Officer · Since at least Aug 30, 2022 |
| Wilford Dean Baker | Director · Since at least Apr 6, 2021 |
Log in to ask 6ix AI your own questions about Vivani Medical, Inc.